Literature DB >> 33627997

Injection-Site Nodules Associated With Once-Weekly Subcutaneous Administration of Semaglutide.

Elizabeth B Hearn1, Justin J Sherman1.   

Abstract

Entities:  

Year:  2021        PMID： 33627997      PMCID： PMC7887535          DOI： 10.2337/ds20-0033

Source DB:  PubMed          Journal:  Diabetes Spectr        ISSN： 1040-9165


× No keyword cloud information.
  11 in total

Review 1.  Adverse Effects of GLP-1 Receptor Agonists.

Authors:  Theodosios D Filippatos; Thalia V Panagiotopoulou; Moses S Elisaf
Journal:  Rev Diabet Stud       Date:  2015-02-10

Review 2.  Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy.

Authors:  Kristy Iglay; Xiting Cao; Panagiotis Mavros; Kruti Joshi; Shengsheng Yu; Kaan Tunceli
Journal:  Clin Ther       Date:  2015-08       Impact factor: 3.393

3.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

Authors:  M A Nauck; U Niedereichholz; R Ettler; J J Holst; C Orskov; R Ritzel; W H Schmiegel
Journal:  Am J Physiol       Date:  1997-11

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

5.  Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Authors:  John B Buse; Michael Nauck; Thomas Forst; Wayne H-H Sheu; Sylvia K Shenouda; Cory R Heilmann; Byron J Hoogwerf; Aijun Gao; Marilyn K Boardman; Mark Fineman; Lisa Porter; Guntram Schernthaner
Journal:  Lancet       Date:  2012-11-07       Impact factor: 79.321

Review 6.  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

7.  Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes.

Authors:  Deborah Hinnen
Journal:  Diabetes Spectr       Date:  2017-08

8.  Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone.

Authors:  Kayla Riswold; Valerie Flynn
Journal:  JAAD Case Rep       Date:  2018-09-18

9.  Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.

Authors:  S Christopher Jones; Debra L Ryan; Valerie S W Pratt; Ali Niak; Allen D Brinker
Journal:  Diabetes Spectr       Date:  2015-11

Review 10.  Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors.

Authors:  William H Polonsky; Robert R Henry
Journal:  Patient Prefer Adherence       Date:  2016-07-22       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.